Q-omics provides the consensus-scored FMR1 profile across patient tissues and cancer cell-line models. FMR1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FMR1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, FMR1 RNA expression shows 20,562 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where FMR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FMR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FMR1 survival associations across molecular data types. FMR1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FMR1 RNA expression–survival associations across cancer types. High FMR1 expression shows unfavorable associations in ESCA, but favorable associations in KIRC, SCLC, SKCM, OV and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FMR1 RNA expression.
This table summarizes FMR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FMR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FMR1 shows higher tumor expression in HNSC, LIHC, BLCA, CHOL, STAD and COAD. The HNSC box plot shows higher FMR1 RNA expression in tumor versus normal tissue (log2 FC = +1.250, t-test p < 0.001).
This table shows molecular features associated with FMR1 in patient tissues and cancer cell lines. In patient samples, FMR1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FMR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
